GACM
MYGN icon

Global Alpha Capital Management’s Myriad Genetics MYGN Stock Holding History

Global Alpha Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-484,100
Closed -$13.2M – 42
2019
Q4 		$13.2M Buy
484,100
+226,400
+88% +$6.23M 1.96% 19
2019
Q3 		$7.38M Sell
257,700
-11,300
-4% -$329K 1.28% 31
2019
Q2 		$7.47M Buy
+269,000
New +$7.6M 1.3% 33

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Global Alpha Capital Management's MYGN Position: Q1 2020 in Review

Global Alpha Capital Management sold out of Myriad Genetics (MYGN) in Q1 2020, closing a stake of 484,100 shares — an estimated $13.2M sold.

Global Alpha Capital Management first reported a position in MYGN in Q2 2019 and held it in 3 quarters. The position peaked at $13.2M in Q4 2019. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2020.

  • Global Alpha Capital Management reported no remaining Myriad Genetics position as of Q1 2020 after selling out during the quarter.
  • Global Alpha Capital Management sold 484,100 Myriad Genetics shares in Q1 2020, an estimated $13.2M.
  • Global Alpha Capital Management first reported a position in Myriad Genetics in Q2 2019 and held it in 3 quarters.
  • Global Alpha Capital Management's Myriad Genetics position peaked at $13.2M in Q4 2019.
  • 190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2020.

Based on Global Alpha Capital Management's 13F filing for Q1 2020, filed 13 May 2020.